Viking Therapeutics Inc Total Liabilities
Viking Therapeutics Inc total liabilities. Based on the latest financial reports, Viking Therapeutics Inc (VKTX) has total liabilities worth $113.58 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See VKTX defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Viking Therapeutics Inc (2012–2025)
Total liabilities of Viking Therapeutics Inc from 2012 to 2025. This chart illustrates how Viking Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Check asset resilience ratio of Viking Therapeutics Inc to evaluate the company's liquid asset resilience ratio.
Viking Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Viking Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Cofinimmo SA
BR:COFB
|
Belgium | €2.88 Billion |
|
Renasant Corporation
NYSE:RNST
|
USA | $22.90 Billion |
|
H&E Equipment Services Inc
NASDAQ:HEES
|
USA | $2.07 Billion |
|
Independence Realty Trust Inc
NYSE:IRT
|
USA | $2.58 Billion |
|
Xinjiang Tianshan Cement Co Ltd
SHE:000877
|
China | CN¥192.09 Billion |
|
Adata Technology Co Ltd
TWO:3260
|
Taiwan | NT$35.06 Billion |
|
Strauss Group
TA:STRS
|
Israel | ILA5.19 Billion |
|
CMB.TECH NV
BR:CMBT
|
Belgium | €5.82 Billion |
Liability Composition Analysis (2012–2025)
This chart breaks down Viking Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see VKTX asset base.
Liquidity & Leverage Metrics
Viking Therapeutics Inc Total Liabilities Ratios Explained
Viking Therapeutics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.72 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.28 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.22 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Viking Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Viking Therapeutics Inc (2012–2025)
The table below shows the annual total liabilities of Viking Therapeutics Inc from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $76.67 Million | +173.39% |
| 2024-12-31 | $28.04 Million | +39.72% |
| 2023-12-31 | $20.07 Million | -13.51% |
| 2022-12-31 | $23.21 Million | +164.38% |
| 2021-12-31 | $8.78 Million | -27.80% |
| 2020-12-31 | $12.16 Million | +70.35% |
| 2019-12-31 | $7.14 Million | +56.44% |
| 2018-12-31 | $4.56 Million | -47.30% |
| 2017-12-31 | $8.66 Million | +33.32% |
| 2016-12-31 | $6.49 Million | -3.30% |
| 2015-12-31 | $6.71 Million | -73.33% |
| 2014-12-31 | $25.17 Million | +5740.32% |
| 2013-12-31 | $431.00K | +308.86% |
| 2012-12-31 | $105.42K | -- |
About Viking Therapeutics Inc
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steato… Read more